CorMedix Bets That One Sales Force Can Do the Work of Two

Every drug sold in a hospital needs someone to sell it. That means sales reps walking the same hallways and calling on the same surgeons. When two small companies send separate teams into the same buildings, someone is paying twice for the same work. That idea sits at the center of a deal announced today. CorMedix Inc. (NASDAQ: CRMD) has agreed to buy substantially all of the assets of Heron Therapeutics, Inc. (NASDAQ: HRTX) for cash and stock worth about $222.6 million upfront, based on CorMedix’s closing share price on Friday. 

CorMedix already works in this world. Its main product, DefenCath, helps protect patients with catheters from bloodstream infections, and last year’s purchase of Melinta Therapeutics added a shelf of antibiotics. Heron’s four drugs fit beside them. ZYNRELEF eases pain after surgery. APONVIE keeps patients from waking up sick to their stomachs. CINVANTI and SUSTOL do a similar job for people going through chemotherapy. All are given in hospitals, surgery centers, or infusion clinics that CorMedix’s reps already visit. 

Heron came to the table weakened. Its third-quarter revenue slipped 7.8% from a year earlier to $35.3 million, and it finished September with $23.4 million in cash and investments. In August, it pulled its 2026 sales forecast and said it was weighing strategic alternatives. Selling its products lets Heron pay off its loan from Hercules. 

The price comes in layers. The first is $145 million in cash. The second is 14,583,333 CorMedix shares, a number fixed by dividing $105 million by $7.20. That count is locked, so Heron carries the risk if CorMedix’s stock falls before closing. The third layer is a promise: up to $55 million tied to ZYNRELEF sales in 2028, plus a 5% royalty on combined sales of CINVANTI, SUSTOL, and certain licensed products above $25 million in each of 2027, 2028, and 2029.

The ZYNRELEF targets are a stretch. Heron collects $25 million if the drug’s 2028 net sales reach $65 million, and another $30 million if they reach $95 million. Its $10.6 million third quarter points to about $42 million a year. The first target requires roughly 50% growth in two years. The second requires sales to more than double. 

Heron does not disappear once its drugs are gone. It stays on Nasdaq with no products but some valuable leftovers: cash, CorMedix stock, the earn-out and royalty rights, and about $2.3 billion in federal and state net operating losses. Those losses can shelter future profits from tax, and the board plans to look for acquisitions or investments, possibly outside biotech. It must hold its CorMedix shares for six months and can name one CorMedix director while it owns at least 10%. 

CorMedix’s side of the bet is about savings. The company says the deal will add to earnings and free cash flow right away and expects to cut between $45 million and $60 million in yearly costs by the end of 2027, mostly by removing duplicate sales, administrative, and public company costs. Set that against the $125 million to $150 million the Heron drugs are expected to bring in during 2027, and the savings equal roughly a third to almost half of the revenue. The harder question is whether a smaller sales team can keep a drug like ZYNRELEF growing. 

The deal also leans on debt. CorMedix signed a secured loan of up to $150 million with funds managed by Pharmakon Advisors and plans to draw $75 million at closing. The rate is three-month SOFR plus 5.75%, with SOFR treated as no lower than 3.50%, so CorMedix pays at least 9.25%. That is about $6.9 million a year in interest. CorMedix shareholders also absorb about 14.6 million new shares. 

The deal is expected to close in the first quarter of 2027, once a majority of Heron’s shareholders approve it and U.S. antitrust regulators sign off. Holders of about 22% of Heron’s stock, including Rubric Capital, have pledged their votes. After that, the story belongs to the sales reps. If CorMedix can trim costs and still push ZYNRELEF higher, both companies come out ahead. If the cuts slow the drugs down, Heron’s earn-outs shrink and lost sales eat into CorMedix’s savings.